Traders Buy Shares of Pfizer (PFE) on Weakness

Investors bought shares of Pfizer Inc. (NYSE:PFE) on weakness during trading on Monday. $115.56 million flowed into the stock on the tick-up and $55.87 million flowed out of the stock on the tick-down, for a money net flow of $59.69 million into the stock. Of all companies tracked, Pfizer had the 22nd highest net in-flow for the day. Pfizer traded down ($0.29) for the day and closed at $36.06

A number of research analysts recently weighed in on the stock. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. BMO Capital Markets set a $37.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, October 10th. Barclays set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, Jefferies Group set a $38.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research report on Monday, October 16th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $38.77.

The company has a market capitalization of $214,943.11, a price-to-earnings ratio of 14.42, a P/E/G ratio of 2.54 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same period in the prior year, the company earned $0.61 earnings per share. The firm’s revenue was up .9% on a year-over-year basis. analysts anticipate that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, December 1st. Shareholders of record on Friday, November 10th were issued a dividend of $0.32 per share. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.59%. Pfizer’s dividend payout ratio is currently 79.01%.

In other news, insider Sally Susman sold 38,230 shares of the stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the sale, the insider now directly owns 145,649 shares of the company’s stock, valued at $5,097,715. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the completion of the sale, the executive vice president now directly owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 60,280 shares of company stock valued at $2,118,988. 0.06% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Shine Investment Advisory Services Inc. bought a new position in Pfizer during the second quarter valued at $102,000. Mckinley Capital Management LLC Delaware bought a new position in Pfizer during the second quarter valued at $103,000. D. Scott Neal Inc. lifted its position in Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares during the last quarter. Herndon Capital Management LLC bought a new position in Pfizer during the second quarter valued at $120,000. Finally, Franklin Parlapiano Turner & Welch LLC bought a new position in Pfizer during the first quarter valued at $121,000. 69.89% of the stock is owned by hedge funds and other institutional investors.

WARNING: This story was reported by Community Financial News and is owned by of Community Financial News. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.com-unik.info/2017/12/06/traders-buy-shares-of-pfizer-pfe-on-weakness.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit